DEF: Canopy Growth Seeks Share Consolidation Amidst Volatility

Canopy Growth Corporation will hold its 2025 Annual General and Special Meeting to vote on director elections, auditor re-appointment, executive compensation, and a proposed share consolidation to maintain Nasdaq listing.

Summary

• Shareholders will vote on five director nominees, the re-appointment of PKF O'Connor Davies LLP as auditor, a share consolidation proposal, and an advisory vote on executive compensation at the Annual General and Special Meeting on September 26, 2025.
• The proposed share consolidation ratio ranges from one post-consolidation share for every five to fifteen pre-consolidation shares, aimed at maintaining Nasdaq listing compliance.
• Luc Mongeau was appointed CEO effective January 6, 2025, with a base salary of C$975,000 and a compensation package designed to align with market benchmarks and industry dynamics.
• Former CEO David Klein's base salary was adjusted to US$750,000 before his transition to Special Advisor and planned retirement on August 31, 2025.
• Executive short-term incentive payouts for Fiscal 2025 totaled 77.6% of target, reflecting underperformance against financial metrics (17.6% of revenue target, 29.3% of Adjusted EBITDA target) but superior achievement of corporate objectives.
• The company reported a net loss of US$416 million and Adjusted EBITDA of US$16 million for Fiscal 2025.
• Total debt was reduced by C$293 million (49%) in Fiscal 2025, leading to an approximate US$33 million reduction in annual interest payments.
• Consolidated Gross Margins increased by 300 basis points and Canada Cannabis Gross Margins by 700 basis points in Fiscal 2025 compared to Fiscal 2024.
• Selling, General & Administrative expenses (excluding divested businesses) decreased by 18% in Fiscal 2025 compared to Fiscal 2024.
• Canopy USA completed acquisitions of Acreage, Wana, and a majority ownership of Jetty during Fiscal 2025.

Sentiment

Score: 4

Explanation: The company is actively addressing its financial challenges through debt reduction, cost management, and strategic acquisitions. However, the significant decline in share price, missed financial targets, and the necessity of a reverse stock split to maintain Nasdaq listing indicate substantial underlying issues and a challenging operating environment. While management is taking corrective actions, the current financial performance and market perception are weak.

Positives

• Successfully reduced total debt by C$293 million (49%) in Fiscal 2025, leading to an approximate US$33 million reduction in annual interest payments.
• Achieved increased Consolidated Gross Margins by 300 basis points and Canada Cannabis Gross Margins by 700 basis points in Fiscal 2025 compared to Fiscal 2024.
• Reduced Selling, General & Administrative expenses by 18% in Fiscal 2025 (excluding divested businesses).
• Canada medical cannabis net revenue increased by 16% in Fiscal 2025 compared to Fiscal 2024.
• Storz & Bickel delivered C$73 million in net revenue in Fiscal 2025, a 4% increase over Fiscal 2024, driven by strong demand for the Venty portable vaporizer.
• Completed strategic acquisitions of Acreage, Wana, and a majority ownership of Jetty through Canopy USA, positioning for U.S. THC market opportunity.
• Executive compensation adjustments and a new CEO appointment aim to align pay with performance and reflect the company's evolving size and focus on profitability.
• Corporate objectives, including cash management, new product development, and international product sourcing, were achieved at a superior level.

Negatives

• The company's share price experienced a significant decline, falling from C$100 on March 31, 2020, to C$0.71 on March 31, 2025, and dipped below the Nasdaq minimum bid price of $1.00 on several days in March and April 2025.
• Short-term incentive payouts for Named Executive Officers were 77.6% of target, primarily due to achieving only 17.6% of the revenue target and 29.3% of the Adjusted EBITDA target, reflecting financial underperformance despite meeting corporate objectives.
• Total Shareholder Return (TSR) performance was significantly negative, with FY25 TSR at -87% and 3-year Cumulative TSR (FY23-FY25) at -99%.
• The company reported a net loss of US$416 million and Adjusted EBITDA of US$16 million for Fiscal 2025.
• The employment of Judy Hong, former Chief Financial Officer, was terminated without cause on July 9, 2025.
• The need for a share consolidation proposal highlights the company's struggle to maintain its Nasdaq listing due to a low share price.

Risks

• Nasdaq Delisting Risk: The company's share price has recently dipped below the Nasdaq minimum bid price of $1.00, and there is no assurance that the proposed share consolidation will effectively or sustainably raise the price to maintain listing.
• Market Price Volatility: The market price of shares after consolidation may not increase as anticipated or be sustained, and the total market capitalization could decrease.
• Liquidity Impact: A reduced number of outstanding shares post-consolidation could adversely affect the liquidity of the shares.
• Fractional Shares: Shareholders may lose value from fractional shares being cancelled for no consideration during consolidation.
• Industry Headwinds: Broader cannabis industry headwinds, continued market volatility, and significant price compression across core products impact financial performance.
• Regulatory Uncertainty: Changes to the U.S. cannabis regulatory roadmap and the uncertain position of the Trump administration on cannabis rescheduling pose ongoing risks.
• Operational Costs: Rising energy costs contribute to increased operating costs, depressing margins.
• Capital Requirements: Continued capital requirements through the issuance of additional common shares could further affect share performance.

Future Outlook

The company's strategic priorities include leveraging its position in the global cannabis market, focusing on sustainable profitability in global medical cannabis and the Canadian adult-use market, and continuing cost reduction efforts across all business areas. Integration of recent acquisitions through Canopy USA is underway to capitalize on the U.S. THC market opportunity.

Management Comments

• The Board aims to provide clear and comprehensive disclosure of the Company's oversight and decision making. We continue to welcome any feedback as the Board and the Company continue to evolve.
• Mr. Mongeau's compensation package was designed to reflect both market benchmarks and the unique dynamics of the cannabis industry, which remains volatile.
• This overall reduction in compensation aligns with the Company's compensation philosophy disclosed above and is aimed at ensuring competitiveness in the executive compensation landscape while prudently managing cash costs.
• The executive team's performance in these areas [cash management, new product development, international sourcing] was critical to maintaining operational discipline, fostering innovation, and positioning the Company for future growth.
• The leadership transition was part of a planned succession, not a broader organizational restructuring.
• The Board believes that requiring that there be a Lead Director in the event the Chair of the Board is not an Independent Director is appropriate at this time to provide the most effective leadership structure for Canopy Growth in the rapidly evolving and highly-regulated cannabis industry.
• The Board is committed to ensuring diversity amongst the directors and senior management of the Company.
• We actively seek opportunities to enhance our DEI strategy through a variety of initiatives. We are investing time, resources and leadership engagement to achieve our desired results and achieve meaningful progress.
• The Board believes that the primary responsibilities of directors are to exercise their business judgment in good faith and to act in what they reasonably believe is in the best interests of the Company and its Shareholders.
• The Company seeks to discourage its employees from frequent buying and selling of securities for the purpose of realizing short-term profits and to acquire securities as long-term investments only.
• The Company understands the importance of succession planning.
• The Company values input from its Shareholders and is respectful of their right to communicate any concerns they may have to leadership of the Company.
• We believe that our executive compensation program and policies are designed to align the interests of management with the long-term interests of Shareholders.

Industry Context

The company operates within a rapidly evolving and highly-regulated cannabis industry, characterized by significant volatility, broader industry headwinds, and continued market price compression. Changes to the U.S. cannabis regulatory roadmap and the uncertain position of the Trump administration on cannabis rescheduling are noted as significant external factors impacting the sector. The company's strategic focus on global medical cannabis and Canadian adult-use markets, alongside its Canopy USA acquisitions, reflects efforts to navigate and capitalize on opportunities within this challenging landscape.

Comparison to Industry Standards

• The company uses a dual peer group approach (Canadian Consumer-Focused Group and U.S. CPG and Pharmaceutical Group, both including cannabis companies) for benchmarking executive compensation to reflect competitive pay levels in both jurisdictions.
• For Fiscal 2023 PSU awards, Relative Total Shareholder Return (TSR) was measured against a custom group of cannabis industry peers including Curaleaf Holdings, Green Thumb Industries, Tilray, Cronos Group, Sundial Growers, Aurora Cannabis, OrganiGram Holdings, and Charlottes Web Holdings.
• The company's share price performance declined significantly compared to both the S&P/TSX Composite Index and the Horizons Marijuana Life Sciences Index ETF from April 1, 2020, to March 31, 2025, indicating underperformance relative to broader market and cannabis sector benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Theresa Yanofsky, a current director, served on the board of Reitmans (a Canadian retailer) when it filed for Companies' Creditors Arrangement Act (CCAA) protection in May 2020, with a plan of arrangement sanctioned in January 2022.
• Shan Atkins, a current director, served on the board of LSC Communications, Inc. when it filed for Chapter 11 bankruptcy in April 2020, with assets acquired in December 2020.
• Joe Bayern, a director nominee, served as CEO of GCC MSO Management LLC, which had a receiver appointed in February 2025, after his departure in October 2024.

Related Party Transactions

• Constellation Brands, Inc. (CBI) Group, a significant shareholder, holds 26,261,474 Exchangeable Shares, representing approximately 9.9% of the issued and outstanding Shares on an as-converted basis.
• On April 18, 2024, Greenstar (a CBI affiliate) converted approximately C$81.2 million of the CBI Note principal into 9,111,549 Exchangeable Shares, and the CBI Group exchanged all 17,149,925 Shares they collectively held for Exchangeable Shares.
• Following these conversions, the Amended Investor Rights Agreement and other commercial arrangements between the company and CBI were terminated on April 18, 2024, meaning CBI no longer holds governance rights in relation to Canopy Growth.

Stakeholder Impact

• Shareholders: Potential for increased share price and Nasdaq listing maintenance if share consolidation is successful, but also risks of further price decline, reduced liquidity, and loss of value from fractional shares. Executive compensation is tied to performance, but past TSR has been poor.
• Employees: Executive compensation structure aims to attract and retain talent, with a focus on aligning pay with performance. DEI initiatives are in place to foster an inclusive workplace.
• Customers: Strategic focus on new product development (e.g., Claybourne infused pre-rolls, Storz & Bickel Venty vaporizer) and expanding product assortment in medical cannabis aims to enhance customer satisfaction.
• Creditors: Debt reduction efforts (C$293 million in FY25) and extension of senior secured term loan maturity to September 2027 improve the company's financial stability and ability to meet obligations.

Next Steps

• Hold the 2025 Annual General and Special Meeting on September 26, 2025, for shareholder votes on key proposals.
• Potentially implement the approved share consolidation at the Board's discretion anytime prior to September 26, 2026, to maintain Nasdaq listing.
• Continue integration of Acreage under new leadership at Canopy USA.
• Ongoing efforts to improve profitability, sharpen commercial execution, and strengthen operational performance, including positioning the Global Medical platform for accelerated growth and tightening focus in Canadian adult-use.
• Luc Mongeau to continue leading the company as CEO, focusing on business transformation and strategic leadership.
• Annual review of executive compensation and corporate governance practices by the CGCN Committee.

Key Dates

Recommendation

While Canopy Growth faces significant challenges, evidenced by its substantial share price decline and the need for a share consolidation to maintain Nasdaq listing, the company is actively implementing strategic initiatives to improve its financial health. These include aggressive debt reduction, cost management, and a sharpened focus on profitable segments like global medical cannabis and key adult-use products. The recent acquisitions through Canopy USA also position the company for future growth in the U.S. THC market. However, the cannabis industry remains highly volatile, and the company's ability to consistently achieve financial targets and sustain a higher share price is unproven. Given the ongoing efforts to stabilize and reposition the business, a 'hold' recommendation is appropriate for investors willing to tolerate high risk and monitor the execution of these strategic shifts, rather than a 'sell' which would imply a lack of confidence in the turnaround efforts, or a 'buy' which would be premature given the current performance and market conditions.

Keywords

Cannabis, SEC Filing, Proxy Statement, Share Consolidation, Nasdaq Listing, Executive Compensation, Corporate Governance, Financial Performance, Canopy Growth, Marijuana, THC, CPG, Risk Management, Debt Reduction, Gross Margins, Adjusted EBITDA, Storz & Bickel, Canopy USA, Acreage, Wana, Jetty